Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 633

1.

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.

Rovithi M, Gerritse SL, Honeywell RJ, Ten Tije AJ, Ruijter R, Peters GJ, Voortman J, Labots M, Verheul HMW.

J Clin Oncol. 2018 Dec 26:JCO1800725. doi: 10.1200/JCO.18.00725. [Epub ahead of print]

PMID:
30586316
2.

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, W├╝rdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E.

EBioMedicine. 2018 Dec 20. pii: S2352-3964(18)30602-9. doi: 10.1016/j.ebiom.2018.12.025. [Epub ahead of print]

3.

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance.

de Klerk DJ, Honeywell RJ, Jansen G, Peters GJ.

Cancers (Basel). 2018 Dec 10;10(12). pii: E503. doi: 10.3390/cancers10120503. Review.

4.

Targeting the ribosome biogenesis key molecule fibrillarin to avoid chemoresistance.

El Hassouni B, Sarkisjan D, Vos JC, Giovannetti E, Peters GJ.

Curr Med Chem. 2018 Dec 3. doi: 10.2174/0929867326666181203133332. [Epub ahead of print]

PMID:
30501594
5.

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.

Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Gilli A, Honeywell R, Chartoire M, Peters GJ, Giovannetti E; Italian Oncological Group of Clinical Research (GOIRC).

Br J Cancer. 2018 Nov;119(11):1326-1331. doi: 10.1038/s41416-018-0307-3. Epub 2018 Nov 8.

PMID:
30405211
6.

Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.

Petri GL, Cascioferro S, Parrino B, Peters GJ, Diana P, Giovannetti E.

Pharmacogenomics. 2018 Jul 1;19(10):811-814. doi: 10.2217/pgs-2018-0071. Epub 2018 Jun 19. No abstract available.

PMID:
29916298
7.

Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks.

van Meerbeeck JP, Jansen G, Giovannetti E, Peters GJ.

Eur Respir J. 2018 May 24;51(5). pii: 1800817. doi: 10.1183/13993003.00817-2018. Print 2018 May. No abstract available.

PMID:
29794125
8.

Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.

Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2018;37(6):329-339. doi: 10.1080/15257770.2018.1460479. Epub 2018 May 3.

PMID:
29723133
9.

High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients.

Meijer B, Seinen ML, Hosman T, Linskens RK, Kneppelhout JK, Peters GJ, Mulder CJ, van Bodegraven AA, de Boer NK.

Nucleosides Nucleotides Nucleic Acids. 2018;37(6):317-323. doi: 10.1080/15257770.2018.1460477. Epub 2018 May 3.

PMID:
29723116
10.

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ.

Cancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25.

11.

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.

Toffalorio F, Santarpia M, Radice D, Jaramillo CA, Spitaleri G, Manzotti M, Catania C, Jordheim LP, Pelosi G, Peters GJ, Tibaldi C, Funel N, Spaggiari L, de Braud F, De Pas T, Giovannetti E.

Oncotarget. 2018 Feb 16;9(23):16437-16450. doi: 10.18632/oncotarget.24505. eCollection 2018 Mar 27.

12.

Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies.

Gade DR, Makkapati A, Yarlagadda RB, Peters GJ, Sastry BS, Rajendra Prasad VVS.

Comput Biol Chem. 2018 Jun;74:63-75. doi: 10.1016/j.compbiolchem.2018.02.014. Epub 2018 Feb 24.

PMID:
29547875
13.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.

14.

Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group.

Perego P, Hempel G, Linder S, Bradshaw TD, Larsen AK, Peters GJ, Phillips RM; EORTC PAMM Group.

Cancer Chemother Pharmacol. 2018 Mar;81(3):427-441. doi: 10.1007/s00280-017-3502-7. Epub 2017 Dec 28. Review.

PMID:
29285635
15.

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.

Muller IB, de Langen AJ, Giovannetti E, Peters GJ.

Onco Targets Ther. 2017 Sep 13;10:4535-4541. doi: 10.2147/OTT.S109493. eCollection 2017. Review.

16.

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.

Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struys EA, Perrino M, Jansen G, Matherly LH, Peters GJ.

Ann Oncol. 2017 Nov 1;28(11):2725-2732. doi: 10.1093/annonc/mdx499.

17.

The potential of multi-compound nanoparticles to bypass drug resistance in cancer.

Da Silva CG, Peters GJ, Ossendorp F, Cruz LJ.

Cancer Chemother Pharmacol. 2017 Nov;80(5):881-894. doi: 10.1007/s00280-017-3427-1. Epub 2017 Sep 8. Review.

18.

Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies.

Murahari M, Prakash KV, Peters GJ, Mayur YC.

Eur J Med Chem. 2017 Oct 20;139:961-981. doi: 10.1016/j.ejmech.2017.08.023. Epub 2017 Aug 12.

PMID:
28886509
19.

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.

Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E.

Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087. eCollection 2017 Aug 8.

20.

A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.

Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E.

Drug Resist Updat. 2017 Mar;31:43-51. doi: 10.1016/j.drup.2017.07.001. Epub 2017 Jul 24. Review.

PMID:
28867243

Supplemental Content

Loading ...
Support Center